OCUL earnings date and last-quarter result: last quarter beat, P/E -5.88. Updated 2026-07-23.
Ocular Therapeutix (OCUL) Research Hub
Ocular Therapeutix (OCUL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.47 USD (-0.46%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.88, market cap 1.90B. This hub links to the full technical, earnings and options research available for OCUL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.47 USD (-0.46%) |
| 52-week range | 6 USD – 11.74 USD |
| Trend regime | Range |
| 14-day RSI | 34.8 (Bearish) |
| Trailing P/E | -5.88 |
| Market cap | 1.90B |
| Dividend yield | 0.00% |
Available research for OCUL
Covered Call on OCUL: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OCUL: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OCUL: how it works, illustrative setup around the real 6.47 USD price, max profit/loss, breakeven and when to use it. Educational.
OCUL technical analysis: range, last 6.47 USD, RSI 34.8, 52w range 6 USD–11.74 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is OCUL in?
Ocular Therapeutix (OCUL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OCUL in an uptrend or downtrend?
As of 2026-10-26, OCUL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OCUL's trailing P/E ratio?
OCUL's trailing P/E is -5.88, with a market cap of 1.90B. See the earnings research page for full valuation detail.